Doxecitine
As of the edition of 20 October 2026, Doxecitine is a small molecule: marketed, first approved in 2025 (US); US protection ends in 2030.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Kygevvi
- First approved
- 3 November 2025 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- UCB; 2 holders in all
- Registered trials
- 7, 1 stopped early
- Disease areas
- Bones, joints and muscles; Nervous system; Nutrition and metabolism; Blood and lymph; Cancer; Chemically induced
US protection
US protection ends in 2030.
The last listed US exclusivity ends in 2030. The application that gives this date is held by UCB.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 1 | 2 | 1 | 1 | 0 |
| Phase 2 | 2 | 1 | 1 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| UCB | Originator and Lead sponsor of trials | 2026 to now |